Valion Bio Secures $250K in New Tranche of Preferred Stock and Warrants
VBIO is trading near its 52-week low of $0.511 (5.9% above the low) on light trading volume (0.3× avg).
Summary
Valion Bio received $250,000 from an investor by issuing preferred stock and warrants, providing critical capital for the financially distressed company.
Key Events · Financing and Capital Events · VBIO
-
New Capital Infusion
Valion Bio issued 250 Series B Preferred Shares at $1,000 per share and warrants to purchase 156,026 common shares to 3i, LP, for an aggregate purchase price of $250,000.
-
Part of Existing Agreement
This transaction is a tranche closing under a previously announced Securities Purchase Agreement for up to $8.4 million, initiated in April 2025.
-
Addresses Liquidity Concerns
The financing provides crucial capital for the company, which recently reported a going concern warning and Nasdaq minimum bid price non-compliance.
-
Dilutive Structure
The issuance of preferred stock and warrants is dilutive to existing common shareholders. The warrant exercise price is $0.616280 per share, which is above the current stock price of $0.5411.
Analysis · VBIO · Life Sciences
Valion Bio, a company recently flagged with a going concern warning and Nasdaq minimum bid price non-compliance, has secured an additional $250,000 in financing. This capital infusion, part of a larger $8.4 million agreement, is crucial for extending the company's operational runway and addressing its immediate liquidity challenges, despite the dilutive impact on existing shareholders.
How filings like this one have moved
In the 30 days to Oct 4, 2026, 36.7% of the 997 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VBIO was trading at $0.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8M. The 52-week trading range was $0.51 to $5.60. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.